Clinical, Functional, and Nutritional Efficacy of a Glutamine-Enriched Oligomeric Diet in Patients with Rectal Cancer.
Study Goal
The researchers aimed to evaluate the efficacy of a glutamine-enriched oligomeric diet (GEOD) compared to a standard polymeric diet (SPD) in reducing oncology treatment-related diarrhea and gastrointestinal toxicity in rectal cancer patients.
Results Summary
The GEOD arm showed improved stool consistency and a greater reduction in stool frequency compared to the SPD arm, indicating a protective effect against gastrointestinal toxicity associated with chemotherapy and radiotherapy.
Population
Patients with rectal cancer undergoing neoadjuvant chemotherapy and radiotherapy who were at risk of malnutrition.
Effective Dosage
400 ml of GEOD or SPD daily.
Duration
From the start of radiotherapy to 30 days after its completion.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
glutamine-enriched oligomeric diet (GEOD) | increase | stool consistency | patients with rectal cancer in treatment with neoadjuvant chemotherapy and radiotherapy who were at risk of malnutrition | - | improved | #1 |
glutamine-enriched oligomeric diet (GEOD) | decrease | number of stools | patients with rectal cancer in treatment with neoadjuvant chemotherapy and radiotherapy who were at risk of malnutrition | - | greater reduction in | #2 |
glutamine-enriched oligomeric diet (GEOD) | decrease | gastrointestinal toxicity associated with chemotherapy and radiotherapy treatment | patients with rectal cancer | - | had a protective effect in terms of the development of | #3 |
AIMS: This work aims to evaluate the efficacy of nutritional supplementation with a glutamine-enriched oligomeric diet (GEOD) compared to a standard polymeric diet (SPD) in terms of oncology treatment-related diarrhea (OTRD) (frequency and consistency of stools), gastrointestinal toxicity, and functional and nutritional progress. METHODS: This prospective cohort study compared two groups of patients with rectal cancer in treatment with neoadjuvant chemotherapy and radiotherapy who were at risk of malnutrition. Patients were randomized to receive either 400 ml of GEOD or of SPD from the start of radiotherapy to 30 days after its completion. RESULTS: Eighty patients were recruited, 40 per arm. The GEOD arm had improved stool consistency and a greater reduction in the number of stools compared to the SPD arm ( CONCLUSIONS: GEOD had a protective effect in terms of the development of gastrointestinal toxicity associated with chemotherapy and radiotherapy treatment in patients with rectal cancer.